Portuguese-based pharmaceutical company Somai Pharmaceuticals recently announced its entry into the Australian market. The company plans to collaborate with American e-cigarette company Airo Brands to manufacture and distribute a range of e-cigarette and e-liquid products.
Pharmaceutical company Somei operates a 3800-square-meter factory near Lisbon, where it exclusively produces the Airo e-cigarette battery technology and its AiroPod e-liquid formula. The first batch of products is expected to be launched in the second quarter of this year under the Special Access Scheme, and sales are also anticipated in Germany, Poland, and Switzerland.
Airo Company was established in 2017 and its innovative tobacco products have been licensed for sale in more than 1700 medical and adult-use marijuana dispensaries across 23 states in the United States and Puerto Rico.
For Solmax, a company engaged in the extraction, research, development, formulation, and distribution of pharmaceutical cannabis products complying with EU GMP regulations, the Airo product holds the potential to become their first batch of products distributed in Australia.
Somai Founder and CEO, Michael Sassano, expressed that this collaboration will position Airo "ahead of other companies in global expansion." He stated, "Our Airo products will meet the European Union GMP quality standards worldwide, and as the global market expands, we will propel the entire Airo product range into an even brighter future." Both Europe and other continents are progressing, and we are honored to bring the finest vaporizers to the global market.
Richard Yost, CEO of Airo, has referred to this collaboration as a "milestone" and emphasized the significance of finding a partner that shares their commitment to quality and consumer focus. According to Yost, they have identified these qualities in Soma.
We were not only impressed by their advanced factory in Portugal, but also by the quality of their team.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
